Read all articles form Edition 2 of the ESMO Perspectives.
Read all articles from Edition 6 of the ESMO Perspectives.
Read all articles from Edition 7 of the ESMO Perspectives.
Read all articles from Edition 8 of the ESMO Perspectives.
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments
In recent conflicts, good response to the health needs of refugees with cancer in receiving countries is consequence of an analysis of local cancer centres capacity and special measures to avoid fragmented care
ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach
Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance
A virtual space where to discuss the how the doctor-patient relationship is evolving in oncology. Prof. Alberto Sobrero has been the Head of the Medical Oncology Unit at Ospedale San Martino in Genova, Italy, since 2001.
A virtual space where to discuss the latest achievements in precision oncology. Dr Garralda directs the Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, at Vall d' Hebron Institute of Oncology (VHIO), Barcelona, Spain. She is also Principal Investigator of VHIO’s Early Clinical Drug Development Group.
A virtual space where to reflect on sustainability in cancer care. Dr Trapani is a fellow at the Dana Farber Cancer Institute, Boston, US. He has collaborated with the World Health Organization as a consultant of the cancer control team for two years.
In neighbouring countries, oncologists are seeing a growing number of female refugees with breast cancer whose treatment may have started before they left Ukraine and urgently needs to be continued for good outcomes to be achieved.
Treating patients at reduced doses could contribute to a more efficient allocation of healthcare resources and improve access to costly treatments around the world, but implementation of de-escalation in routine practice requires reliable and cost-effective tools to safely tailor therapy to patients
Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.